Hims & Hers Health（HIMS）股价周四上涨约7%。此前，小罗伯特·F·肯尼迪表示，美国食品药品监督管理局（FDA）正在考虑调整对肽类药物的限制，此举可能缓解这家远程医疗公司面临的部分监管压力。
肯尼迪表示，FDA正在考虑将12种肽类药物从二级限制清单中移除。他补充说，另有7种肽类药物将于7月接受审查，预计在2027年2月之前还将进行更多讨论。
这一潜在转变之所以重要，是因为肽类药物被用于某些复方制剂中，而这一领域近年来受到监管机构更为严格的审查。对Hims & Hers而言，任何规则的放宽都可能提振其减重及健康业务相关领域的市场情绪。
Hims & Hers股价此前已保持强劲上涨势头，而这一最新消息进一步激发了投资者对该股的兴趣。随着交易员对该公司未来可能迎来更有利监管环境的预期做出反应，其股价延续了此前的涨势。
责任编辑：张俊 SF065
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.